1. ACQUIRED ANTIBODIES TO FACTOR II
Patients with antiphospholipid antibodies occasionally have antibody specificity to coagulation factor II (prothrombin), leading typically to a severe hypoprothrombinemia and bleeding. Mixing studies may or may not reveal presence of an inhibitor, as the antibody typically binds a non-enzymatically active portion of the molecule that leads to accelerated clearance, but characteristically the PT is prolonged and levels of factor II are low. FFP should be administered for treatment of bleeding. Treatment is immunosuppressive.
2. ACQUIRED ANTIBODIES TO FACTOR V
Products containing bovine factor V (such as topical thrombin or fibrin glue, frequently used in surgical procedures) can lead to formation of an anti–factor V antibody that cross-reacts with human factor V. Clinicopathologic manifestations range from a prolonged PT in an otherwise asymptomatic individual to severe bleeding. Mixing studies suggest the presence of an inhibitor, and the factor V activity level is low. In cases of serious or life-threatening bleeding, IVIG or platelet transfusions, or both, should be administered, and immunosuppression (as for acquired inhibitors to factor VIII) may be offered.
3. ACQUIRED ANTIBODIES TO FACTOR VIII
Spontaneous antibodies to factor VIII (acquired hemophilia A) occasionally occur in adults without a prior history of hemophilia; older adults and patients with lymphoproliferative malignancy or connective tissue disease and those who are postpartum or postsurgical are at highest risk. The clinical presentation, which should be viewed as a medical emergency, typically includes extensive soft tissue ecchymoses, hematomas, and mucosal bleeding, as opposed to hemarthrosis characteristic of congenital hemophilia A. The aPTT is typically prolonged and does not correct upon mixing; factor VIII activity is found to be low and a Bethesda assay reveals the titer of the inhibitor. Inhibitors of low titer (less than 5 BU) may often be overcome by infusion of high doses of factor VIII concentrates, whereas high-titer inhibitors (greater than 5 BU) must be treated with serial infusions of activated prothrombin complex concentrates, recombinant human activated factor VII, or recombinant porcine factor VIII (hemophilia A patients only). Along with establishment of hemostasis by one of these measures, immunosuppressive treatment with corticosteroids with or without oral cyclophosphamide or rituximab should be instituted; treatment with IVIG and plasmapheresis can be considered in refractory cases. Unlike in congenital factor VIII deficiency, the patient’s bleeding does not correlate well with the factor VIII activity level, so the clinician must be concerned with any elevation of aPTT secondary to acquired factor VIII inhibitor. All such patients require immediate referral to a hematologist.
J. FVIII inhibitors: pathogenesis and avoidance. Blood. 2015 Mar 26;125(13):2045–51.
et al. Clinical problem-solving. A Bruising Loss. N Engl J Med. 2016 Jul 7;375(1):76–81.
et al. Laboratory diagnosis of acquired hemophilia A: limitations, consequences, and challenges. Semin Thromb Hemost. 2014 Oct;40(7):803–11.